is a biotech
company located in Mechelen
. It provides a quantitative phenotype
prediction for HIV
resistance testing. The prediction is achieved by performing a search in a database of genotype-phenotype pairs and matching the mutations in the database with those of the sample of the patient (Nearest neighbor search
). A phenotype is predicted which provides information on the resistance of the virus to treatment.
Virco was founded in 1995
by Rudi Pauwels
(Rega Institute for Medical Research
) and Paul Stoffels
). Over the years the company built up a database on all the possible mutations of the AIDS
virus and the ways in which drugs reacted to these mutations. The company acted as a partner to other companies such as LabCorporation
. LabCorp., and others, sent the blood samples of AIDS patients to Virco, where tests were carried out into the virus's possible resistance to the anti-HIV drugs. On 21 March 2002
the company was acquired by Johnson & Johnson
- Larder BA, Kemp SD, Hertogs K. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (VirtualPhenotype), Antiviral Therapy. 2000;5 (suppl 3):49.